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A Rare Case of Primary Hyperparathyroidism Associated with 
Primary Aldosteronism, Hürthle Cell Thyroid Cancer and 
Meningioma
 Multiple endocrine neoplasia type 1 (MEN1) syndrome includes varying combinations of 
endocrine and non-endocrine tumors. There are also a considerable number of atypical 
MEN1 syndrome. In this case, a 68-yr-old woman was referred to the Department of 
Endocrinology for hypercalcemia. Five years ago, she had diagnosed as primary 
hyperaldosteronism and now newly diagnosed as parathyroid hyperplasia with laboratory 
and pathologic findings. Hürthle-cell thyroid cancer was also resected during the 
parathyroid exploration and small meningioma was found on brain MRI. Her general 
condition has markedly improved and her adrenal mass and meningioma are being closely 
observed now. We could find the loss of heterozygosity of the MEN1 locus in parathyroid 
glands, suggesting a MEN1-related tumor, but not a germline mutation. Considering a 
variety of phenotypic expression and a limitation of current molecular analysis, periodic 
follow up will be needed in patients with a MEN1-like phenotype.
Key Words: Hyperparathyroidism; Primary Hyperaldosteronism; Thyroid Cancer, Hürthle-
cell; Meningioma
You Lim Kim
1, Young Woo Jang
1, 
Jin Taek Kim
1, Su Ah Sung
1, 
Tae Seok Lee
2, Won Mi Lee
3, 
and Hyo Jeong Kim
1
Departments of 
1Internal Medicine, 
2General 
Surgery, and 
3Pathology, Eulji University School of 
Medicine, Seoul, Korea
Received: 30 October 2011
Accepted: 26 January 2012
Address for Correspondence:
Hyo Jeong Kim, MD
Department of Internal Medicine, Division of Endocrinology and 
Metabolism, Eulji University School of Medicine, Eulji General 
Hospital, 14 Hangeulbiseok-gil, Nowon-gu, Seoul 139-872, 
Korea
Tel: +82.2-970-8558, Fax: +82.2-970-8227
E-mail: kimhj@eulji.ac.kr
http://dx.doi.org/10.3346/jkms.2012.27.5.560  •  J Korean Med Sci 2012; 27: 560-564
CASE REPORT
Endocrinology, Nutrition & Metabolism
INTRODUCTION
Multiple endocrine neoplasia type 1 (MEN1) syndrome is an 
autosomal dominant inherited disorder, which predisposes pa-
tients to the development of varying combinations of endocrine 
and non-endocrine tumors (1). They include the hyperplasia or 
adenoma of the parathyroid gland, and tumors of the endocrine 
pancreas and anterior pituitary (2). However, primary aldoste-
ronism is one of the conditions rarely associated with MEN1 (3). 
It has also been reported that meningiomas are related to MEN1 
(4). The candidate gene, MEN1, is located on chromosome 11q13 
and loss of heterozygosity (LOH) of the MEN1 locus appears to 
MEN1-related tumors (5). Here we report a rare case consisting 
of primary hyperparathyroidism associated with primary aldo-
steronism, Hürthle-cell thyroid carcinoma, and meningioma.
CASE DESCRIPTION
A 68-yr-old woman was referred to the Department of Endocri-
nology for an elevated serum calcium level (2.95 mM, normal 
value: 2.25-2.75 mM) on May 24, 2010. Five years earlier, she 
had visited to the Department of Nephrology for evaluation of 
hypokalemia. At that time, she had been diagnosed with primary 
hyperaldosteronism with a low potassium level (1.7 mM, nor-
mal value: 3.5-5.3 mM), a high plasma aldosterone level (0.244 
nM, normal value: 0.014-0.083 nM), and a low normal plasma 
renin level (0.021 pM, normal value: 0.008-0.3 pM). Adrenal CT 
scan showed a 1-cm round nodule in the left adrenal gland (1.1 
× 1.0 cm), suggestive of adrenal adenoma (Fig. 1A). At that time, 
she refused an operation and started to take spironolactone. 
After 5 months, however, she did not visit the outpatient clinic 
any more.
  Two years before the presentation reported here, she came 
to the Department of Neurology, complaining of the involuntary 
movement of her neck and four extremities. She was referred 
again to the Department of Nephrology with a similarly low po-
tassium level (1.8 mM, normal value: 3.5-5.3 mM), and high 
plasma aldosterone level (aldosterone 0.327 nM, normal value: 
0.014-0.083 nM),and low normal plasma renin level (0.040 pM, 
normal value: 0.008-0.3 pM). On the follow-up CT scan, the size 
of the left adrenal adenoma had slightly increased since the pre-
vious film (1.4 × 1.2 cm) (Fig. 1B). She started to take 50 mg of 
spironolactone again. Because of other vague symptoms like 
depression, anxiety, headache, nausea, anorexia, and polydip-
sia, it was also recommended that she visit a neuropsychiatric 
clinic under the suspicion of manic depressive disorder.Kim YL, et al.  •  Atypical Combinations of MEN1-like Phenotype 
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  When she visited the Department of Endocrinology due to 
hypercalcemia, she had taken spironolactone for 2 yr, maintain-
ing a normal potassium level. She had been taking antihyper-
tensive medication for 20 yr and hypoglycemic agents for 2 yr. 
She had no family history of the endocrine tumors such as para-
thyroid gland, pancreas or pituitary gland. Further studies dem-
onstrated that her hypercalcemia was associated with an elevat-
ed intact-PTH level (83.2 ng/L, normal value 14-72 ng/L). An 
increased parathyroid uptake of MIBI scan was noted in the right 
superior, right inferior, and left inferior parathyroid glands (Fig. 2). 
Multiple cystic and solid nodules, suggestive of malignancy, were 
incidentally found in both thyroid glands by neck sonography 
and fine needle aspiration cytology (Fig. 3). During the parathy-
roid exploration, total thyroidectomy was performed at once. 
The pathological diagnosis of the resected parathyroid glands 
was chief cell hyperplasia and that of the thyroid gland was Hürth-
le-cell carcinoma (Fig. 2, 3).
  Due to her lasting headache during hospital days, we per-
formed an imaging study. On her brain MRI, a small meningio-
ma (2.1 × 2.0 × 1.4 cm) was detected, as a non-endocrine tumor, 
in the left parasagital-frontoparietal convexity (Fig. 4); however, 
there were no pituitary lesions. We decided to follow up on the 
meningioma without surgery because of the small mass size 
and no correlating symptoms. Her general condition markedly 
improved and her adrenal mass and meningioma are now be-
ing closely observed.
  Based on these results, we could conclude that she had prima-
ry hyperparathyroidism, primary hyperaldosteronism, Hürthle-
cell carcinoma of the thyroid gland, and meningioma. From 
various clinical manifestations, we suspected that the findings 
of the patient might have been related to a MEN1 mutation or 
other genetic background. In the analysis of all coding exons of 
MEN1 of the patient, polymorphisms were detected in exon 9 
and exon 10, but failed to show a germline mutation (Fig. 5A). 
However, we could find the LOH of the MEN1 locus at codon 
1269 (C1269T), in exon 9 of the parathyroid gland, suggesting a 
A B
Fig. 2. The radiologic and pathologic findings of parathyroid glands. (A) Parathyroid MIBI scan showed an increased uptake in the right superior/inferior and left inferior glands. 
(B) The pathological diagnosis of the resected parathyroid glands were chief cell hyperplasia, H&E stain, × 200.
A B
Fig. 1. The serial radiologic findings of adrenal lesion. (A) The first CT scan showed a 1-cm round nodule in left adrenal gland (1.1 × 1 cm). (B) The size of it slightly increased 
(1.4 × 1.2 cm) on the following CT scan three years later.Kim YL, et al.  •  Atypical Combinations of MEN1-like Phenotype 
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MEN1-related tumor (Fig. 5B). In case of the thyroid glands, there 
was no LOH of MEN1 locus at codon 1269 (Fig. 5C).
DISCUSSION
We report here a rare case consisting of primary hyperparathy-
roidism associated with primary hyperaldosteronism, Hürthle-
cell thyroid carcinoma, and meningioma. We suspected those 
serial findings might have come from a MEN1 mutation and 
Fig. 3. The radiologic and pathologic findings of thyroid glands. (A) Multiple thyroid 
nodules were incidentally found in preoperative neck US. (B, C) The resected tumor 
of thyroid gland shows a capsular invasion, consisting solid Hürthle-cells and vari-
able sized follicles, suggestive of Hürthle-cell carcinoma. H&E stain, B × 20; C × 400.  C
A B
Fig. 4. In the left parasagital-frontoparietal convexity of brain MRI, a small meningioma 
(2.1 × 2.0 × 1.4 cm) was newly detected.
A
B
C
Fig. 5. Direct sequence analysis of all coding exons of MEN1 of the patient. (A) Blood 
cell DNA failed to show a germline mutation. (B) DNA from the parathyroid hyperpla-
sia showed a LOH of the MEN1 locus at codon 1269 (C1269T), in exon 9. (C) On the 
other hand, LOH of MEN1 locus was not detected in DNA from the thyroid tissue. Kim YL, et al.  •  Atypical Combinations of MEN1-like Phenotype 
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tested this using genomic DNA from peripheral blood leuko-
cytes. In this patient, we could not find a germline mutation in 
the protein-coding lesion of the MEN1 gene, but detected the 
LOH of the MEN1 locus in exon 9 of the parathyroid gland, sug-
gesting a MEN1-related tumor.
  A practical definition of MEN1 states that a patient must have 
abnormalities in at least two of the affected endocrine glands, 
as well as a first-degree relative with at least one MEN1-related 
lesion or a known MEN1 mutation (2, 6). This usually involves 
the parathyroids (95%), pancreas (40%), or pituitary (29%), but 
occasionally other endocrine glands are affected as well (7, 8). 
Our patient had a parathyroid lesion, but neither pancreas nor 
the pituitary lesions. However, it is well known that MEN1 mu-
tation relates to combinations of over 20 different endocrine 
and non-endocrine tumors (1). Thus, no simple definition of 
MEN1 could cover all index cases or all families. Some research-
ers have called those atypical types of patients as ‘MEN1 pheno-
copy’ or ‘MEN1 phenocopy variants’.
  The prevalence of adrenal lesions in MEN1 ranges from 9% 
to 55% (3, 8), and is generally reported to be rarer than those of 
parathyroid or pancreatic endocrine lesions (11, 12). Further-
more, “functional” aldosterone-producing adrenocortical ade-
noma is rarely seen. In earlier studies, some researchers found 
LOH of the 11q13 locus in aldosterone-producing adrenal ade-
noma (8, 9). It was notable that primary hyperparathyroidism 
was newly detected after treating hyperaldosteronism with spi-
ronolactone. It has been reported that hypercalcemia might be 
masked for a while under hyperaldosteronism, which causes 
hypokalemic alkalosis and a low serum ionized calcium (13).
  Thyroid disease can be observed in over 25% of MEN1 pa-
tients (12). Even though there have been a few reports of papil-
lary thyroid cancer (14-16), no report has associated Hürthle-
cell thyroid cancer with MEN1-like syndrome. In this case, we 
found Hürthle-cell thyroid cancer incidentally during explora-
tion. Although we could not find somatic changes like LOH           
of the MEN1 locus in the thyroid tissue, this is the first report       
of Hürthle-cell thyroid cancer combined with MEN1-like phe-
notype.
  Meningioma was also accompanied by other endocrine tu-
mors in this patient. Asgharian et al. recently reported that me-
ningiomas developed in 6 of 74 (8%) MEN1 patients with pan-
creatic endocrine tumors (PETs) prospectively. According to 
them, meningiomas were 11 times more frequent in patients 
with PETs and MEN1 than without it (4). Bäcklund et al. (17) also 
studied the relationship between parathyroid adenoma and 
primary CNS tumors, particularly meningiomas. They reported 
that the incidence of meningiomas in patients with parathyroid 
adenoma was much higher than in those without it . Although 
more research is needed, there might be a shared etiology of 
parathyroid adenomas and meningiomas.
  The MEN1 gene is a tumor suppressor gene on chromosome 
11q13 that encodes the nuclear protein, menin, which regulates 
cell growth and cycle, and when this protein deficit occurs, MEN1 
develops (10). In addition, LOH at the locus of the MEN1 tumor 
suppressor gene may have an important role in the develop-
ment of tumor (5). In this patient, we found the LOH of the MEN1 
locus of the parathyroid gland, but could not detect a germline 
mutation in the MEN1 gene. There might be several explana-
tions for the lack of definite mutations. First, the sensitivity of 
the PCR and direct sequencing method is generally 60%-70%. 
MEN1 germline mutations have been identified in about 80% 
to 90% of probands with familial MEN1 syndrome (2) and about 
65% of individuals with simplex MEN1 syndrome (5). There is 
no doubt about the usefulness of MEN1 mutation analysis to 
confirm a diagnosis of MEN1, but we should also note the limi-
tation of genetic analysis indicated above. Next, approximately 
10% of new germline mutations are being detected among all 
MEN1 patients, which is one of the reasons why the association 
of genotype and phenotype could not be identical in our case. 
Based on a few recent studies, the incidence of CDKN1B muta-
tions in patients with a MEN1-related phenotype is estimated 
to be 1.5%-3.7% (18-20).
  Our patient has shown more than two endocrine tumors over 
several years, suggesting MEN1-related clinical features. In this 
patient, we found the LOH of the MEN1 locus of the parathyroid 
gland, but could not detect a germline mutation in the MEN1 
gene. Considering a variety of phenotypic expression and a lim-
itation of current molecular analysis, periodic screening and 
follow up will be needed in the patient who have a MEN1-like 
phenotype but test-negative for MEN1 mutations. 
REFERENCES
1. Marsh DJ, Gimm O. Multiple endocrine neoplasia: types 1 and 2. Adv 
Otorhinolaryngol 2011; 70: 84-90.
2. Brandi ML, Gagel RF, Angeli A, Bilezikian JP, Beck-Peccoz P, Bordi C, 
Conte-Devolx B, Falchetti A, Gheri RG, Libroia A, et al. Guidelines for 
diagnosis and therapy of MEN type 1 and type 2. J Clin Endocrinol Metab 
2001; 86: 5658-71.
3. Langer P, Cupisti K, Bartsch DK, Nies C, Goretzki PE, Rothmund M, 
Röher HD. Adrenal involvement in multiple endocrine neoplasia type 1. 
World J Surg 2002; 26: 891-6.
4. Asgharian B, Chen YJ, Patronas NJ, Peghini PL, Reynolds JC, Vortmeyer 
A, Zhuang Z, Venzon DJ, Gibril F, Jensen RT. Meningiomas may be a com-
ponent tumor of multiple endocrine neoplasia type 1. Clin Cancer Res 
2004; 10: 869-80.
5. Guo SS, Sawicki MP. Molecular and genetic mechanisms of tumorigenesis 
in multiple endocrine neoplasia type-1. Mol Endocrinol 2001; 15: 1653-64.
6. Schussheim DH, Skarulis MC, Agarwal SK, Simonds WF, Burns AL, 
Spiegel AM, Marx SJ. Multiple endocrine neoplasia type 1: new clinical 
and basic findings. Trends Endocrinol Metab 2001; 12: 173-8.
7. Thakker RV. Multiple endocrine neoplasia type 1 (MEN1). Best Pract Res 
Clin Endocrinol Metab 2010; 24: 355-70.Kim YL, et al.  •  Atypical Combinations of MEN1-like Phenotype 
564   http://jkms.org http://dx.doi.org/10.3346/jkms.2012.27.5.560
8. Beckers A, Abs R, Willems P, Van der Auwera B, Kovacs K, Reznik M, 
Stevenaert A. Aldosterone-secreting adrenal adenoma as part of multi-
ple endocrine neoplasia type 1 (MEN1): loss of heterozygosity for poly-
morphic chromosome 11 deoxyribonucleic acid markers, including the 
MEN1 locus. J Clin Endocrinol Metab 1992; 75: 564-70.
9. Iida A, Blake K, Tunny T, Klemm S, Stowasser M, Hayward N, Gordon R, 
Nakamura Y, Imai T. Allelic losses on chromosome band 11q13 in aldo-
sterone-producing adrenal tumors. Genes Chromosomes Cancer 1995; 
12: 73-5.
10. Uchino S, Noguchi S, Sato M, Yamashita H, Yamashita H, Watanabe S, 
Murakami T, Toda M, Ohshima A, Futata T, et al. Screening of the MEN1 
gene and discovery of germ-line and somatic mutations in apparently 
sporadic parathyroid tumors. Cancer Res 2000; 60: 5553-7.
11. Waldmann J, Bartsch DK, Kann PH, Fendrich V, Rothmund M, Langer P. 
Adrenal involvement in multiple endocrine neoplasia type 1: results of     
7 years prospective screening. Langenbecks Arch Surg 2007; 392: 437-43. 
12. Skogseid B, Larsson C, Lindgren PG, Kvanta E, Rastad J, Theodorsson E, 
Wide L, Wilander E, Oberg K. Clinical and genetic features of adreno-
cortical lesions in multiple endocrine neoplasia type 1. J Clin Endocrinol 
Metab 1992; 75: 76-81.
13. Rossi E, Sani C, Perazzoli F, Casoli MC, Negro A, Dotti C. Alterations of 
calcium metabolism and of parathyroid function in primary aldoste-
ronism, and their reversal by spironolactone or by surgical removal of 
aldosterone-producing adenomas. Am J Hypertens 1995; 8: 884-93.
14. Desai D, McPherson LA, Higgins JP, Weigel RJ. Genetic analysis of a pap-
illary thyroid carcinoma in a patient with MEN1. Ann Surg Oncol 2001; 
8: 342-6.
15. Vortmeyer AO, Lubensky IA, Skarulis M, Li G, Moon YW, Park WS, Weil 
R, Barlow C, Spiegel AM, Marx SJ, et al. Multiple endocrine neoplasia 
type 1: atypical presentation, clinical course, and genetic analysis of mul-
tiple tumors. Mod Pathol 1999; 12: 919-24.
16. Kim HJ, Park JS, Kim CS, Kang ES, Cha BS, Lim SK, Kim KR, Lee HC, 
Ahn CW. A case of multiple endocrine neoplasia type 1 combined with 
papillary thyroid carcinoma. Yonsei Med J 2008; 49: 503-6.
17. Bäcklund LM, Grandér D, Brandt L, Hall P, Ekbom A. Parathyroid ade-
noma and primary CNS tumors. Int J Cancer 2005; 113: 866-9.
18. Marinoni I, Pellegata NS. p27kip1: a new multiple endocrine neoplasia 
gene? Neuroendocrinology 2011; 93: 19-28.
19. Molatore S, Marinori I, Lee M, Pulz E, Ambrosio MR, degli Uberti EC, 
Zatelli MC, Pellegata NS. A novel germline CDKN1B mutation causing 
multiple endocrine tumors: clinical, genetic and functional character-
ization. Hum Mutat 2010; 31: E1825-35.
20. Agarwal SK, Mateo CM, Marx SJ. Rare germline mutations in cyclin-de-
pendent kinase inhibitor genes in multiple endocrine neoplasia type 1 
and related states. J Clin Endocrinol Metab 2009; 94: 1826-34.